Investment Rating - The report maintains an "Accumulate" rating for the company, Rabbit Baby (002043) [2][8]. Core Views - The company achieved a slight revenue increase of 1.39% year-on-year, reaching 9.189 billion yuan, while the net profit attributable to shareholders decreased by 15.11% to 585 million yuan due to impairment provisions [5][6]. - The company's revenue from decorative materials, which constitutes 80.58% of total revenue, grew by 7.99%, while the custom home business saw a significant decline of 18.73% [5][6]. - Management and financial expenses decreased significantly, indicating improved cost control and operational efficiency [5][6]. Summary by Relevant Sections Financial Performance - In 2024, the company reported total revenue of 9.189 billion yuan, a 1.39% increase year-on-year, and a net profit of 585 million yuan, down 15.11% [5][6]. - The fourth quarter saw a revenue drop of 18.21% year-on-year, with a net profit decrease of 55.75% [5][6]. - Basic earnings per share for 2024 were 0.71 yuan, with a proposed cash dividend of 3.2 yuan per 10 shares [5][6]. Business Segments - Decorative materials revenue was 7.404 billion yuan, up 7.99%, while custom home revenue fell to 1.720 billion yuan [5][6]. - The custom home segment's retail business grew by 18.49%, but the engineering business saw a decline of 46.81% [5][6]. Cost Management - Sales, management, and financial expenses were reported as 316 million, 204 million, and -34 million yuan respectively, with management expenses decreasing by 23.04% [5][6]. - The overall expense ratio was 5.99%, reflecting a decrease of 0.74 percentage points [5][6]. Profitability Metrics - The company's gross margin remained stable at 18.18%, with a slight decrease of 0.32 percentage points from the previous year [5][6]. - The asset-liability ratio at the end of 2024 was 46.59%, down 0.98 percentage points year-on-year [5][6]. Future Outlook - The company is expected to achieve earnings per share of 0.94 yuan and 1.10 yuan for 2025 and 2026, respectively, with corresponding price-to-earnings ratios of 11.7 and 10 [6][7].

Investment Rating - The report upgrades the investment rating of the company to "Buy" [7] Core Views - The company achieved significant revenue growth in 2024, with total revenue reaching 1.443 billion yuan, a year-on-year increase of 84.92%, and net profit attributable to shareholders reaching 732 million yuan, up 144.27% [3][6] - In Q1 2025, the company continued to show strong growth, with revenue of 366 million yuan, a year-on-year increase of 62.51%, and net profit attributable to shareholders of 169 million yuan, up 66.25% [3][6] - The company has expanded its product matrix and strengthened its technological barriers, receiving a third-class medical device registration for a new injectable product [6] Summary by Sections Financial Performance - In 2024, the company's medical device sales generated revenue of 1.254 billion yuan, a growth of 84.37%, with a gross margin of 95.03% [6] - The functional skincare segment saw an 86.83% increase in revenue, driven by the growth of the "重源" and "ProtYouth" brands [6] - The company’s revenue from raw materials and other segments increased by 89.07%, attributed to stable procurement from brand clients and rising brand awareness [6] Q1 2025 Performance - The company reported a gross margin of 90.11% in Q1 2025, a decrease of 1.78 percentage points year-on-year, but net profit margin improved by 0.94 percentage points to 45.99% due to effective cost control [6] - Sales and management expense ratios decreased by 2.6 and 2.58 percentage points respectively, while R&D expense ratio increased by 0.64 percentage points, indicating a balance between cost control and innovation investment [6] Future Earnings Forecast - The company is projected to achieve earnings per share of 11.88 yuan and 16.50 yuan for 2025 and 2026 respectively, with corresponding price-to-earnings ratios of 33 times and 23 times [7][8]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected stock performance that will exceed the market index by more than 15% over the next six months [1][8]. Core Insights - The company reported a total revenue of 10.778 billion yuan for 2024, representing a year-on-year growth of 21.04%, and a net profit attributable to shareholders of 1.552 billion yuan, up 30% [3]. - In Q1 2025, the company achieved a total revenue of 2.359 billion yuan, with a year-on-year increase of 8.13%, and a net profit of 390 million yuan, growing by 28.87% [3]. - The company continues to strengthen its core capabilities and expand its brand matrix, focusing on the "6*N" strategy to enhance competitiveness [5]. Financial Performance Summary - For 2024, the company’s revenue by category includes skincare at 9.019 billion yuan (up 19.31%), beauty makeup at 1.361 billion yuan (up 21.96%), and hair care at 386 million yuan (up 79.41%) [5]. - In Q1 2025, the revenue breakdown shows skincare at 1.869 billion yuan (up 2.5%), beauty makeup at 375 million yuan (up 21.6%), and hair care at 112 million yuan (up 138.7%) [5]. - The average selling price for skincare products in Q1 2025 was 73.62 yuan per unit (up 0.46%), while beauty makeup and hair care saw price declines of 5.48% and 9.79%, respectively [5]. Profitability Metrics - The gross margin for 2024 improved by 1.46 percentage points to 71.39%, with net margin increasing by 0.89 percentage points to 14.71% [5]. - In Q1 2025, the gross margin further increased by 2.67 percentage points to 72.78%, and the net margin rose by 2.75 percentage points to 17.19% [5]. Earnings Forecast - The company is projected to achieve earnings per share of 4.80 yuan in 2025 and 5.76 yuan in 2026, with corresponding price-to-earnings ratios of 16 times and 13 times, respectively [5][6].

Investment Rating - The report maintains an "Overweight" investment rating for the consumer services industry, expecting the industry index to outperform the market index by over 10% in the next six months [33]. Core Insights - In Q1 2025, domestic travel reached 1.794 billion trips, with total spending of 1.8 trillion yuan, reflecting a year-on-year increase of 26.4% in travel volume and 18.6% in spending [25][33]. - The consumer services industry index fell by 3.86% from April 11 to April 24, 2025, underperforming the CSI 300 index by approximately 5.18 percentage points [8]. - The report highlights a recovery trend in tourism consumption, supported by favorable policies such as visa exemptions with Malaysia and Azerbaijan, and a predicted daily cross-regional movement of over 270 million people during the May Day holiday [22][24][33]. Summary by Sections Market Review - The consumer services index experienced a decline, with the tourism and hotel sectors correcting after previous gains. The comprehensive service sector saw a rise of 5.10%, while tourism and hotel sectors fell by 7.28% and 4.38%, respectively [10][13]. - As of April 24, 2025, the overall PE ratio for the consumer services industry was approximately 31.95 times, slightly down from previous levels and below the average valuation of 50.65 times since 2016 [16]. Industry News - Key developments include a significant increase in domestic travel and spending, with Q1 2025 seeing 1.794 billion trips and 1.8 trillion yuan spent, marking increases of 26.4% and 18.6% year-on-year, respectively [25]. - The report notes the extension of visa exemptions with Malaysia and Azerbaijan, which is expected to boost inbound tourism [22]. Company Announcements - Notable company performances include Jiuhua Tourism reporting a 30.13% increase in revenue to 235 million yuan in Q1 2025, driven by a rise in visitor numbers [27]. - Xiangyuan Cultural Tourism reported a 19.64% increase in revenue for 2024, while also providing a Q1 earnings forecast [28]. Weekly Perspective - The report suggests focusing on sectors directly benefiting from local tourism development policies, such as scenic spots and online travel agencies (OTAs), while also considering cyclical sectors like exhibitions and education [33].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock will outperform the market index by more than 15% in the next six months [2][8]. Core Insights - The company, Aier Eye Hospital (300015), reported a total revenue of 20.983 billion yuan for 2024, a year-on-year increase of 3.02%, and a net profit attributable to shareholders of 3.556 billion yuan, up 5.87% [4]. - In Q1 2025, the company achieved a total revenue of 6.026 billion yuan, reflecting a year-on-year growth of 15.97%, and a net profit of 1.05 billion yuan, which is a 16.71% increase compared to the previous year [4]. - The company is focusing on enhancing its core business and digital capabilities, which has contributed to the recovery of its performance growth in Q1 2025 [5]. Summary by Sections Financial Performance - In 2024, the company recorded an outpatient volume of 16.9407 million visits, a 12.14% increase, and a surgical volume of 1.2947 million cases, up 9.38% [5]. - Revenue from various services in 2024 included: refractive services at 7.603 billion yuan (up 2.31%), cataract services at 3.489 billion yuan (up 4.87%), anterior segment services at 1.898 billion yuan (up 5.95%), posterior segment services at 1.499 billion yuan (up 8.22%), and vision care services at 5.279 billion yuan (up 6.42%) [5]. Regional Performance - In 2024, the company achieved revenue growth in several domestic regions, with notable increases in Southwest (5.39%), East China (6.69%), North China (6.28%), South China (3.92%), and Northwest (3.59%) regions, while Central China and Northeast regions saw declines of -4.27% and -2.24% respectively [5]. - Internationally, the company generated 2.625 billion yuan in revenue, a 13.5% increase, with Europe and Southeast Asia growing by 18.05% and 7.51% respectively [5]. Market Potential - The report highlights significant growth potential in China's ophthalmic medical services due to an aging population, increasing prevalence of age-related eye diseases, and rising awareness of eye health among the public [5]. - The current low penetration rates in various ophthalmic specialties indicate a substantial unmet demand for treatment, suggesting that the market for eye health services is likely to expand as awareness and education improve [5]. Earnings Forecast - The company is projected to achieve earnings per share of 0.46 yuan and 0.53 yuan for 2025 and 2026 respectively, with corresponding price-to-earnings ratios of 28 times and 24 times [6].

半导体行业 超配（维持） 半导体行业双周报（2025/04/11-2025/04/24） 行 业 半导体板块 Q1 业绩有望实现同比增长 投资要点： 风险提示：终端需求不及预期、国产替代不及预期、价格竞争加剧等。 2025 年 4 月 25 日 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 刘梦麟 SAC 执业证书编号： S0340521070002 电话：0769-22110619 邮箱： liumenglin@dgzq.com.cn 周 报 陈伟光 S0340520060001 电话：0769-22119430 邮箱： chenweiguang@dgzq.com.cn 行 资料来源：东莞证券研究所，iFind | 1.半导体行业行情回顾 | | 3 | 2.半导体产业新闻 | | 4 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 3.公司公告与动态 | | 5 | 4.半导体产业数据更新 | | 8 | | | | 4.1 | 智能手 ...

10% 医药生物 沪深300 医药生物行业 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/4/11-2025/4/24） 福建省医疗设备集采结果公布 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 -15% -10% -5% 0% 5% -25% -20% -20% -15% -10% 2025 年 4 月 25 日 -30% -25% -35% -35% -30% -25% -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 分析师：谢雄雄 SAC 执业证书编号： S0340523110002 电话：0769-22110925 邮箱： xiexiongxiong@dgzq.com.cn 分析师：魏红梅 SAC 执业证书编号： S0340513040002 ...

Market Performance - The major indices showed mixed performance with the Shanghai Composite Index closing at 3297.29, up by 0.03%, while the Shenzhen Component Index fell by 0.58% to 9878.32 [2] - The ChiNext Index decreased by 0.68% to 1935.86, and the STAR 50 Index dropped by 0.92% to 1003.32 [2] - The total trading volume in the Shanghai and Shenzhen markets was 1.11 trillion, a decrease of 120.7 billion from the previous trading day [6] Sector Performance - The top-performing sectors included Beauty Care (1.61%), Banking (1.16%), and Utilities (1.08%), while the worst-performing sectors were Computer (-2.36%) and Communication (-2.08%) [3] - Concept sectors such as PEEK Materials (3.70%) and Acrylic Acid (1.89%) performed well, whereas New and Next Shares (-3.24%) and Electronic ID (-3.20%) lagged [3] Market Outlook - The market is expected to stabilize as domestic macro policies are set to intensify in the second quarter, with potential monetary easing and fiscal stimulus [6] - The report highlights a shift towards a fundamentals-driven market as earnings reports are released and the political bureau meeting at the end of April clarifies future policy directions [6] - Defensive sectors like banking and electricity, along with consumer and technology sectors, are anticipated to perform well amid ongoing economic recovery [6]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock will outperform the market index by more than 15% in the next six months [2][9]. Core Insights - The company, Wens Foodstuff Group Co., Ltd. (温氏股份), reported a total operating revenue of 104.92 billion yuan for 2024, a year-on-year increase of 16.68%, and a net profit attributable to shareholders of 9.23 billion yuan, up 244.46% year-on-year. For Q1 2025, the company achieved a total operating revenue of 24.33 billion yuan, a growth of 11.37%, and a net profit of 2.00 billion yuan, reflecting a 261.92% increase year-on-year [3][6]. Summary by Sections Financial Performance - In 2024, the company sold 30.18 million pigs, a 14.93% increase year-on-year, with a market share of approximately 4.30%, ranking second among listed companies. The average selling price of live pigs was 16.71 yuan/kg, up 12.83% year-on-year, leading to a revenue of 64.86 billion yuan from the pork business, a 33.71% increase [6]. - The comprehensive cost of pig farming for 2024 was approximately 7.2 yuan/kg, down about 1.2 yuan/kg year-on-year. For Q1 2025, the company sold 8.59 million pigs, a 19.7% increase, generating revenue of 15.48 billion yuan, a 25.7% increase [6]. Chicken Farming Business - The chicken farming segment saw a slight decline in revenue, with 1.208 billion chickens sold in 2024, a 2.09% increase, and a market share of 8.41%. The average selling price for chickens was 13.06 yuan/kg, down 4.60%, resulting in revenue of 35.72 billion yuan, a decrease of 2.58% [6]. - The comprehensive cost of chicken farming decreased to around 6 yuan/kg, down 0.8 yuan/kg year-on-year. In Q1 2025, the company sold 281.59 million chickens, a 5.4% increase, with revenue of 6.84 billion yuan, a 10.5% decrease [6]. Earnings Forecast - The company forecasts EPS of 1.52 yuan and 1.56 yuan for 2025 and 2026, respectively, with corresponding PE ratios of 11.19 and 10.88 [7].

Market Overview - The A-share market is experiencing fluctuations, with the ChiNext Index leading the gains [1] - The Shanghai Composite Index closed at 3296.36, down 0.10%, while the Shenzhen Component Index rose by 0.67% to 9935.80 [2] Sector Performance - The top-performing sectors include: - Automotive: +3.21% - Machinery: +2.47% - Communication: +1.73% - Power Equipment: +1.18% - Electronics: +0.91% [3] - The underperforming sectors include: - Retail: -1.85% - Agriculture: -1.39% - Real Estate: -1.38% - Non-ferrous Metals: -1.26% - Beauty Care: -0.95% [3] Concept Index Performance - The leading concept indices are: - Reducer: +5.18% - Humanoid Robots: +4.58% - Automotive Thermal Management: +3.67% - Flying Cars (eVTOL): +3.54% - Integrated Die Casting: +3.48% [4] - The lagging concept indices are: - Gold Concept: -3.44% - Corn: -2.88% - Dairy: -2.86% - Grain Concept: -2.82% - Community Group Buying: -2.68% [4] Future Outlook - The market is expected to focus on consumption, real estate stability, stock market stability, and support for private enterprises in the second quarter [6] - The upcoming Politburo meeting in April is seen as a critical observation window for new policy announcements [6] - The monetary policy is anticipated to shift from risk prevention to growth stabilization, especially if the Federal Reserve lowers interest rates [6]